DOI QR코드

DOI QR Code

Genetic Factors, Viral Infection, Other Factors and Liver Cancer: An Update on Current Progress

  • Su, Cheng-Hao (Department of Emergency Countermeasure and Information Management, Xiamen Center for Disease Control and Prevention) ;
  • Lin, Yong (Department of Infectious Disease Control, Xiamen Center for Disease Control and Prevention) ;
  • Cai, Lin (Department of Health Statistics and Epidemiology, School of Public Health, Fujian Medical University)
  • Published : 2013.09.30

Abstract

Primary liver cancer is one of the most common cancers at the global level, accounting for half of all cancers in some undeveloped countries. This disease tends to occur in livers damaged through alcohol abuse, or chronic infection with hepatitis B and C, on a background of cirrhosis. Various cancer-causing substances are associated with primary liver cancer, including certain pesticides and such chemicals as vinyl chloride and arsenic. The strong association between HBV infection and liver cancer is well documented in epidemiological studies. It is generally acknowledged that the virus is involved through long term chronic infection, frequently associated with cirrhosis, suggesting a nonspecific mechanism triggered by the immune response. Chronic inflammation of liver, continuous cell death, abnormal cell growth, would increase the occurrence rate of genetic alterations and risk of disease. However, the statistics indicated that only about one fifth of HBV carries would develop HCC in lifetime, suggesting that individual variation in genome would also influence the susceptibility of HCC. The goal of this review is to highlight present level of knowledge on the role of viral infection and genetic variation in the development of liver cancer.

Keywords

Viral infection;genetic variation;liver cancer

References

  1. Akkiz H, Bayram S, Bekar A, et al (2009). G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: casecontrol study. Cancer Epidemiol, 33, 261-4. https://doi.org/10.1016/j.canep.2009.06.001
  2. Antoniou AC, Beesley J, McGuffog L, et al (2010). Common breast cancer susceptibility alleles and the risk of breast cancer of BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res, 70, 9742-54. https://doi.org/10.1158/0008-5472.CAN-10-1907
  3. Ataseven H, Bahcecioglu IH, Kuzu N, et al (2006). The levels of ghrelin, leptin, TNF-alpha, and IL-6 in lever cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators Inflamm, 2006, 78380.
  4. Abu Dayyeh BK, Yang M, Fuchs BC, et al (2011). A functional polymorphism in the epidermal growth factor gene is associated with the risk of hepatocellular carcinoma. Gastroenterology, 141, 141-9. https://doi.org/10.1053/j.gastro.2011.03.045
  5. Adami HQ, Hsing AW, McLaughlin JK, et al (1992). Alcoholism and liver cirrhosis in the etiology of primary liver cancer. Int J Cancer, 51, 898-902. https://doi.org/10.1002/ijc.2910510611
  6. Burchard J, Zhang C, Liu AM, et al (2010). MicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol, 6, 402.
  7. Bao Y, Yan Y, Xu C, et al (2013). MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett, 337, 226-36. https://doi.org/10.1016/j.canlet.2013.05.007
  8. Beasley RP, Lin CC, Hwang LY, et al (1981). Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22707 Men in Taiwan. Lancet, 318, 1129-33. https://doi.org/10.1016/S0140-6736(81)90585-7
  9. Bihrer V, Waidmann O, Friedrich-Rust M, et al (2011). Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One, 6, e26971. https://doi.org/10.1371/journal.pone.0026971
  10. Chan HL, Hui AY, Wong ML, et al (2004). Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 53, 1494-8. https://doi.org/10.1136/gut.2003.033324
  11. Chan HL, Tse CH, Mo F, et al (2008). High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol, 26, 177-82. https://doi.org/10.1200/JCO.2007.13.2043
  12. Chen K, Wei Y, Yang H, Li B (2011). Epidermal growth factor +61 G/A polymorphism and the hepatocellular carcinoma in a Chinese population. Genet Test Mol Biomarkers, 15, 251-5. https://doi.org/10.1089/gtmb.2010.0208
  13. Chen X, Zhang L, Chang Y, et al (2011). Association of TNFalpha genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a Han population. Int J Biol Markers, 26, 181-7. https://doi.org/10.5301/JBM.2011.8580
  14. Cho LY, Yang JJ, Ko KP, et al (2011). Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer, 128, 176-84. https://doi.org/10.1002/ijc.25321
  15. Chu CM, Lin CC, Lin SM, Lin DY, Liaw YF (2012). Viral load, genotypes, and mutants in Hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma. Dig Dis Sci, 57, 232-8. https://doi.org/10.1007/s10620-011-1844-2
  16. Cougot D, Neuveut C, Buendia MA (2005). HBV induced carcinogenesis. J Clin Virol, 34, S75-8.
  17. Du Cl, Wang JD (1998). Increased morbidity odds ratio of primary liver cancer and cirrhosis of the liver among vinyl chloride monomer workers. Occup Environ Med, 55, 528-32. https://doi.org/10.1136/oem.55.8.528
  18. Ezzikouri S, El Feydi AE, Chafik A, et al (2007). The Pro variant of the p53 codon72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res, 37, 748-54. https://doi.org/10.1111/j.1872-034X.2007.00126.x
  19. Gao C, Zhao HC, Li JT, Yao SK (2010). Diabetes mellitus and hepatocellular carcinoma: comparison of Chinese patients with and without HBV-related cirrhosis. World J Gastroenterol, 16, 4467-75. https://doi.org/10.3748/wjg.v16.i35.4467
  20. Gao ZY, Li T, Wang J, et al (2007). Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma. J Gastroenterol, 42,761-8. https://doi.org/10.1007/s00535-007-2085-1
  21. Giannitrapani L, Soresi M, Giacalone A, et al (2011). IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS, 15, 183-6. https://doi.org/10.1089/omi.2010.0093
  22. Gui JH, Tian YP, Wen XY, et al (2011). Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci, 120, 183-93. https://doi.org/10.1042/CS20100297
  23. Hassan MM, Curley SA, Li D, et al (2010). Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer, 116, 1938-46. https://doi.org/10.1002/cncr.24982
  24. Howlader N, Noone AM, Krapcho M, et al (2011). EER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site.
  25. Hung CH, Lee CM, Wang JH, et al (2011). Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer, 128, 2344-52. https://doi.org/10.1002/ijc.25585
  26. Hung CH, Lu SN, Wang JH, et al (2011). Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Antivir Ther, 16, 959-68. https://doi.org/10.3851/IMP1842
  27. Hung CH, Wang JH, Hu TH, et al (2010). Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol, 16, 2265-71. https://doi.org/10.3748/wjg.v16.i18.2265
  28. Imai Y, Tamura S, Tanaka H, et al (2010). Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat, 17, 185-91. https://doi.org/10.1111/j.1365-2893.2009.01163.x
  29. International Agency for Research on Cancer (2008). Word Cancer Report 2008. Lyon: IARC.
  30. International Agency for Research on Cancer (2009). Cancer Incidence and Mortality Worldwide in 2008. Lyon: IARC.
  31. Ito K, Tanaka Y, Orito E, et al (2006). T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin Infect Dis, 42, 1-7. https://doi.org/10.1086/504305
  32. Jardi R, Rodriguez F, Buti M, et al (2001). Role of hepatitis B, C and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutation on viral replicative interference. Hepatology, 34, 404-10. https://doi.org/10.1053/jhep.2001.26511
  33. Jemal A, Bray F, Center MM, et al (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  34. Jorissen RN, Walker F, Pouliot N, et al (2003). Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res, 284, 31-53. https://doi.org/10.1016/S0014-4827(02)00098-8
  35. Koberle V, Kronenberger B, Pleli T, et al (2013). Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer, Epub ahead of print.
  36. Koh WP, Wang R, Jin A, Yu MC, Yuan JM (2013). Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer, 108, 1182-8. https://doi.org/10.1038/bjc.2013.25
  37. Kono S, Ikeda M, Tokudome S, Nishizumi M, Kuratsune M (1987). Cigarette smoking, alcohol and cancer mortality: a cohort study of male Japanese physicians. Jpn J Cancer Res, 78, 1323-8.
  38. Kumar V, Kato N, Urabe Y, et al (2011). Genome-wide association study identifies a susceptibility locus for HCVinduced hepatocellular carcinoma. Nat Genet, 43, 455-8. https://doi.org/10.1038/ng.809
  39. Kummee P, Tangkijvanich P, Poovorawan Y, Hirankarn N (2007). Association of HLA-DRB1*13 and TNF-alpha gene polymorphisms with clearance of chronic hepatitis B infection and risk of hepatocellular carcinoma in Thai population. J Viral Hepat, 14, 841-8.
  40. Lemke LB, Rogers AB, Nambiar PR, Fox JG (2008). Obesity and non-insulin-dependent diabetes mellitus in Swiss-Webster mice associated with late-onset hepatocellular carcinoma. J Endocrinol, 199, 21-32. https://doi.org/10.1677/JOE-07-0588
  41. Lewis BP, Burge CB, Bartel DP (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120, 15-20. https://doi.org/10.1016/j.cell.2004.12.035
  42. Li P, Du Q, Cao Z, et al (2012). Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferonregulatory factor-1 (IRF-1). Cancer Lett, 314, 213-22. https://doi.org/10.1016/j.canlet.2011.09.031
  43. Li Q, Li WW, Fan WB, et al (2012). Type 2 diabetes and hepatocellular carcinoma: A case-control study in patients with chronic hepatitis B. Int J Cancer, 131, 1997-202.
  44. Li YJ, Xie Q, Lu FM, et al (2010). Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int, 30, 112-8. https://doi.org/10.1111/j.1478-3231.2009.02134.x
  45. Liaw J, Marshall G, Yuan Y, et al (2008). Increased childhood liver cancer mortality and arsenic in drinking water in northern Chile. Cancer Epidemiol Biomarkers Prev, 17, 1982-7. https://doi.org/10.1158/1055-9965.EPI-07-2816
  46. Lin SM, Yu ML, Lee CM, et al (2007). Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocelluar carcinoma. J Hepatol, 46, 45-52. https://doi.org/10.1016/j.jhep.2006.08.021
  47. Liu CJ, Chen BF, Chen PJ, et al (2006). Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carries. J Infect Dis, 193, 1258-65. https://doi.org/10.1086/502978
  48. Liu CJ, Chen BF, Chen PJ, et al (2006). Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis, 194, 594-9. https://doi.org/10.1086/505883
  49. Liu F, Li B, Wei Y, et al (2011). XRCC1 genetic polymorphism Arg399Gln and hepatocellular carcinoma risk: a metaanalysis. Liver Int, 31, 802-9. https://doi.org/10.1111/j.1478-3231.2011.02508.x
  50. Liu H, Ye L, Wang QW, Yan QX, Yu JM (2009). Effect of conserved peptide derived from Kunitz domain of hepatitis B virus x protein on the cell cycle and apoptosis of HepG2 cells via the proteasome pathway. Chin Med J, 122, 460-5.
  51. Long XD, Ma Y, Huang HD, et al (2008). Polymorphism of XRCC1 and the frequency of mutation in codon 249 of the p53 gene in hepatocellular carcinoma among Guangxi population, China. Mol Carcinog, 47, 295-300. https://doi.org/10.1002/mc.20384
  52. Long XD, Ma Y, Wei YP, Deng ZL (2006). The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res, 36, 48-55. https://doi.org/10.1016/j.hepres.2006.06.004
  53. Loomba R, Yang HI, Su J, et al (2013). Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol, 177, 333-42. https://doi.org/10.1093/aje/kws252
  54. Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L, et al (2007). Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. BMC Cancer, 7, 162. https://doi.org/10.1186/1471-2407-7-162
  55. Lv L, Wang P, Zhou X, Sun B (2013). Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol, 34, 1451-9. https://doi.org/10.1007/s13277-013-0649-7
  56. Ma L, Teruya-Feldstein J, Weinberg RA (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449, 682-8. https://doi.org/10.1038/nature06174
  57. Mendy ME, Welzel T, Lesi OA, et al (2010). Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat, 17, 115-22. https://doi.org/10.1111/j.1365-2893.2009.01168.x
  58. Meng F, Henson R, Wehbe-Janek H, et al (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133, 647-58. https://doi.org/10.1053/j.gastro.2007.05.022
  59. Ministry of health of the people's republic of China (2010). China health statistical yearbook in 2010. The first edition. Beijing, Peking union medical college press.
  60. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV (1998). Immune pathogenesis of hepatocellular carcinoma. J Exp Med, 188, 341-50. https://doi.org/10.1084/jem.188.2.341
  61. Miyake, Y, Kobashi H, Yamamoto K (2009). Meta-analysis: the effect of interferon on development of hepatocellular carcinoma with patients with chronic hepatitis B virus infection. J Gastroenterol, 44, 470-5. https://doi.org/10.1007/s00535-009-0024-z
  62. Mizuguchi Y, Mishima T, Yokomuro S, et al (2011). Sequencing and bioinformatics-based analyses of the mircoRNA transcriptome in hepatitis B-related hepatocellular carcinoma. PLoS One, 6, e15304. https://doi.org/10.1371/journal.pone.0015304
  63. Mun HS, Lee SA, Kim H, et al (2011). Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocelluar carcinoma in patients with chronic genotype C infections. J Virol, 85, 123-32. https://doi.org/10.1128/JVI.01524-10
  64. Oh JK, Shin HR, Lim MK, et al (2012). Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and co-infected subjects in HBV endemic area:a community-based cohort study. BMC Cancer, 12, 452. https://doi.org/10.1186/1471-2407-12-452
  65. Parkin DM (2006). The global health burden of infectionassociated cancers in the year 2002. Int J Cancer, 8, 3030-44.
  66. Polesel J, Zucchetto A, Montella M, et al (2009). The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol, 20, 353-7.
  67. Porkka KP. Pfeiffer MJ, Waltering KK, et al (2007). MicroRNA expression profiling in prostate cancer. Cancer Res, 67, 6130-5. https://doi.org/10.1158/0008-5472.CAN-07-0533
  68. Qu LS, Jin F, Huang XW, Ge YS (2010). Interferon-$\alpha$ therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. J Surg Oncol, 102, 796-801. https://doi.org/10.1002/jso.21741
  69. Saito I, Miyamura T, Ohbayashi A, et al (1990). Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A, 87, 6547-9. https://doi.org/10.1073/pnas.87.17.6547
  70. Saunders D, Seidel D, Alison M, Lyratzopoulos G (2010). Systematic review: the association between obesity and hepatocellular carcinoma- epidemiological evidence. Aliment Pharmacol Ther, 31, 1051-63.
  71. Shafritz DA, Shouval D, Sherman HI, Hadziuannis SJ, Kew MC (1981). Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocelluar carcinoma. Studies in percutaneous liver biopsies and postmortem tissue specimens. N Engl J Med, 305, 1067-73. https://doi.org/10.1056/NEJM198110293051807
  72. Soga K, Shibasaki K, Aoyagi Y (2005). Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatogastroenterology, 52, 1154-8.
  73. Sopipong W, Tangkivanich P, Payungporn S, Posuwan N, Poovorawan Y. The KIF1B (rs17401966) single nucleotide polymorphism is not associated with the development of HBV-related hepatocellular carcinoma in Thai Patients. Asian Pac J Cancer Prev, 14, 2865-9.
  74. Su H, Yang JR, Xu T, et al (2009). MicroRNA-101, downregulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 69, 1135-42.
  75. Sumbul AT, Akkiz H, Bayram S, et al (2012). p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a casecontrol study. Mol Biol Rep, 39, 1639-47. https://doi.org/10.1007/s11033-011-0903-2
  76. Tanabe KK, Lemoine A, Finkelstein DM, et al (2008). Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA, 299, 53-60.
  77. Tatsukawa M, Takaki A, Shiraha H, et al (2011). Hepatitis B virus core promoter mutations G1613 and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients. BMC Cancer, 11, 458. https://doi.org/10.1186/1471-2407-11-458
  78. Thompson KJ, Swan RZ, Walling TL, et al (2013). Obesity, but not ethanol, promotes tumor incidence and progression in a mouse model of hepatocellular caricinoma in vivo. Surg Endosc, 27, 2782-91. https://doi.org/10.1007/s00464-013-2808-8
  79. Tomimaru Y, Eguchi H, Nagano H, et al (2010). MicroRNA-21 induces resistance to the anti-tumor effect of interferon-$\alpha$/5- fluorouracil in hepatocellular carcinoma cells. Br J Cancer, 103, 1617-26. https://doi.org/10.1038/sj.bjc.6605958
  80. Wang C, Wang X, Gong G, et al (2012). Increased risk of hepatocellular carcinoma in patients with diabete mellitus: A systematic review and meta-analysis of cohort studies. Int J Cancer, 130, 1639-48. https://doi.org/10.1002/ijc.26165
  81. Wang Z, Gao Q, Shi JY, et al (2013). Genetic polymorphism of the kinesin-like protein KIF1B gene and the risk of hepatocellular carcinoma. PLoS One, 25, e62571.
  82. Wei W, Liu F, Liu L, et al (2011). Distinct mutations in MLH1 and MSH2 genes in hereditary non-polyposis colorectal cancer (HNPCC) families from China. BMP Rep, 44, 317-22. https://doi.org/10.5483/BMBRep.2011.44.5.317
  83. Wu CF, Yu MW, Lin CL, et al (2008). Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis, 29, 106-12. https://doi.org/10.1093/carcin/bgm252
  84. Wu D, Jiang H, Gu Q, Zhang D, Li Z (2013). Association between XRCC1 Arg399Gln polymorphism and hepatitis virus related hepatocellular carcinoma risk in Asian population. Tumour Biol, Epub ahead of print.
  85. Yang JQ, Pan GD, Chu GP, et al (2008). Interferon-alpha restrains growth and invasive potential of hepatocellular induced by hepatitis B virus X protein. World J Gastroenterol, 14, 5564-9. https://doi.org/10.3748/wjg.14.5564
  86. Yu ML, Lin SM, Chuang WL, et al (2006). A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther, 11, 985-94.
  87. Yang YF, Zhao W, Zhong YD, et al (2009). Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat, 16, 265-71. https://doi.org/10.1111/j.1365-2893.2009.01070.x
  88. Yin H, Xie F, Zhang J, et al (2011). Combination of interferon-$\alpha$ and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. Cancer Lett, 306, 34-42. https://doi.org/10.1016/j.canlet.2011.02.017
  89. Yoon YJ, Chang HY, Ahn SH, et al (2008). MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 29, 1192-6. https://doi.org/10.1093/carcin/bgn090
  90. Yu MW, Yang SY, Pan IJ, et al (2003). Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst, 95, 1485-8. https://doi.org/10.1093/jnci/djg051
  91. Zhang CH, Xu GL. Jia WD, et al (2009). Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a metaanalysis of randomized controlled trials. Int J Cancer, 124, 2982-8. https://doi.org/10.1002/ijc.24311
  92. Zhang CH, Xu GL, Jia WD, et al (2011). Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a metaanalysis of randomized controlled trials. Int J Cancer, 129, 1254-64. https://doi.org/10.1002/ijc.25767
  93. Zhang HX, Zhai Y, Hu ZB, et al (2010). Genomoe-wide association study identifies 1p36.22 as new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carries. Nat Genet, 42, 755-8. https://doi.org/10.1038/ng.638
  94. Zheng JX, Zeng Z, Zheng YY, et al (2011). Role of hepatitis B virus base core and precore/core promoter mutations on hepatocellular carcinoma in untreated older genotype patients. J Viral Hepat, 18, e423-31. https://doi.org/10.1111/j.1365-2893.2011.01458.x
  95. Zhang J, Yang Y, Yang T, et al (2010). MicroRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppress cell proliferation and tumourigenicity. Br J Cancer, 103, 1215-20. https://doi.org/10.1038/sj.bjc.6605895
  96. Zhang KY, Imazeki F, Fukai K, et al (2007). Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma. Cancer Sci, 98, 1921-9. https://doi.org/10.1111/j.1349-7006.2007.00609.x
  97. Zhao BH, Liu F, Liu S, Niu JJ, et al (2011). A case-control study of the association between human exposure to selected chlorinated pesticides and primary hepatocellular carcinoma. Epidemiology, 22, p S 145.
  98. Zhou J, Yu L, Gao X, et al (2011). Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol, 29, 4781-8. https://doi.org/10.1200/JCO.2011.38.2697
  99. Zhuang PY, Zhang JB, Zhang W, et al (2010). Long-term interferon-$\alpha$ treatment suppresses tumor growth but promotes metastasis capacity in hepatocelluar carcinoma. J Cancer Res Clin Oncol, 136, 1891-900. https://doi.org/10.1007/s00432-010-0848-1

Cited by

  1. Activity and Expression Pattern of NF-κB/P65 in Peripheral Blood from Hepatocellular Carcinoma Patients - Link to Hypoxia Inducible Factor -1α vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6911
  2. Comparison of Viral Hepatitis-Associated Hepatocellular Carcinoma Due to HBV and HCV - Cohort from Liver Clinics in Pakistan vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7563
  3. Role of TGF-β1 in Human Colorectal Cancer and Effects after Cantharidinate Intervention vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.4045
  4. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review) pp.1792-1082, 2014, https://doi.org/10.3892/ol.2014.2727
  5. Hepatitis B virus upregulates the expression of kinesin family member 4A vol.12, pp.3, 2015, https://doi.org/10.3892/mmr.2015.3792
  6. Independent and Additive Interaction Between Tumor Necrosis Factor β +252 Polymorphisms and Chronic Hepatitis B and C Virus Infection on Risk and Prognosis of Hepatocellular Carcinoma: a Case-Control Study vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10209
  7. Molecular Links between Alcohol and Tobacco Induced DNA Damage, Gene Polymorphisms and Patho-physiological Consequences: A Systematic Review of Hepatic Carcinogenesis vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4803
  8. Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6929
  9. Predictive Value of Serum Insulin-like Growth Factor-1 in Hepatocellular Carcinoma vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.613
  10. High Resolution Melting Curve Assay for Detecting rs12979860 IL28B Polymorphisms Involved in Response of Iranian Patients to Chronic Hepatitis C Treatment vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1873
  11. Incidence and mortality of liver cancer in China in 2011 vol.34, pp.3, 2015, https://doi.org/10.1186/s40880-015-0056-0
  12. MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression vol.38, pp.5, 2016, https://doi.org/10.3892/ijmm.2016.2754
  13. Association between PNPLA3 rs738409 polymorphism and hepatocellular carcinoma risk: an updated meta-analysis vol.38, pp.9, 2016, https://doi.org/10.1007/s13258-016-0428-0
  14. Long Non-Coding RNA SNHG6 as a Potential Biomarker for Hepatocellular Carcinoma pp.1532-2807, 2017, https://doi.org/10.1007/s12253-017-0241-3